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Abstract
Over recent years there has been a substantial body of evidence demonstrating strong associations
between transfusion and adverse outcomes, including myocardial, neurological and renal injury, in
a range of clinical settings where transfusion is administered for reasons other than life-threatening
bleeding. The strength of these associations across a range of clinical settings suggests that
confounding and bias, the chief limitations of all observational studies, are unlikely to account for
all of these observations. Given the wide range in transfusion rates in cardiac centres, with up to
100% of patients in some centres exposed to allogenic blood components, this evidence, albeit
circumstantial, presents a strong argument for prospective randomised trials to attempt to
determine, firstly, if transfusion causes adverse outcomes, and secondly, in which patient groups
does the benefit of transfusion outweigh these risks? These issues are discussed in the context of
an article published this month in BMC Medicine.
Background
The development of modern blood services that enable
large-scale allogenic red cell donation, storage and trans-
fusion represents one of the greatest achievements of
modern medicine. It has saved countless lives and is indis-
pensable for the treatment of trauma patients and those
with life-threatening haemorrhage. The early success of
blood transfusion, occurring as it did during wartime,
coupled with advances in storage techniques led to the
widespread use of transfusion for indications where there
is little, if any, evidence of efficacy. With the advent of evi-
dence-based medicine over recent decades, coupled with
the increasing prevalence of electronic prospective clinical
databases, we have seen a large number of retrospective
observational studies that appear to show an association
between transfusion and adverse outcome in a range of
clinical scenarios including cardiac surgery [1], general
surgery [2], acute coronary syndromes [3] and in critical
care [4], to name but a few. In fact, it would seem that,
with very few exceptions [5] there is no evidence of effi-
cacy beyond its use in haemorrhagic shock. The study by
Rogers and colleagues, published this month in BMC
Medicine, is a useful addition to the literature, and is
strengthened by the large numbers of patients considered
and the quality of the analysis performed [6]. In this case,
transfusion was associated with a twofold increase in
infection rates. Other studies have shown similar
increases in cardiac, neurological and renal morbidity
associated with transfusion in cardiac surgery [1,7].
The question as to whether transfusion causes adverse
outcome in cardiac surgery remains unanswered, how-
ever. The Rogers study suffers from the limitations of all
retrospective studies in that it cannot adjust for unmeas-
ured confounders, in this case the use of aprotinin, or a
measure of left ventricular function, or for the likelihood
that there will have been bias in the prescribing of allo-
genic blood, with patients who are more ill being more
likely to receive transfusions than those that are less ill. If
we look for clinical evidence that transfusion causes
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adverse outcome, we can refer only to one study in adults;
the Transfusion Requirements in Critical Care (TRICC)
study [8]. This study, performed in a highly selected group
of critical care patients compared a restrictive (7 g/dL) to
a liberal transfusion threshold (10 g/dL). A total of 100%
of those in the liberal group received an allogenic red
blood cell (RBC) transfusion compared to 67% in the
restrictive group. There was no difference in the primary
endpoint (30-day mortality) between the groups,
although there were some differences in secondary end-
points (myocardial infarction and pulmonary oedema),
and in a secondary analysis in younger and less ill patients
where there was a higher mortality in the liberal threshold
group. This study has therefore not presented incontro-
vertible proof that transfusion is harmful. Moreover, the
TRICC study is over 10 years old and blood storage tech-
niques have changed since then, with the widespread
introduction of leukodepletion in many countries. The
applicability of these findings to other patient groups,
such as cardiac surgery patients, is also unclear. It is unfor-
tunate that our evidence base has not developed over the
last the decade, particularly when one considers the
strength of association between transfusion and adverse
outcome in many studies. In the current study, exposure
to allogenic blood components was associated with an
almost fivefold increase in in-hospital mortality [6], and it
is difficult to see how this could be attributed simply to
confounding and bias. The potential economic burden of
transfusion-associated morbidity is also considerable. In
one study, after adjustment for confounding, transfusion
of a single unit of RBC was associated with a 10% increase
in hospitalisation costs [7]. Randomised trials that iden-
tify transfusion indicators are required if we are to target
this resource to those patients that need it and, if nothing
else, prevent waste of what is a valuable and scarce
resource.
This brings us to the major question raised by the current
study by Rogers and colleagues [7]: when is transfusion
indicated, or rather when do the benefits outweigh the
risks? Undoubtedly many patients undergoing cardiac
surgery develop coagulopathic or surgical bleeding that is
life-threatening and transfusion in this setting is clearly
indicated. In cross-sectional studies in the UK the rate of
re-thoracotomy for severe bleeding ranges from 3% to
10% [9]. Identifying other patients that benefit from
transfusion is more difficult, although some severely
anaemic patients without life-threatening bleeding will in
all probability benefit from RBC transfusion. It is highly
unlikely that 100% of patients undergoing cardiac surgery
in any unit will need or benefit from transfusion however,
as has been described in the current study. Even the lower
confidence limit for transfusion rates in women in the
current study, 72.5%, is high. The relative proportions of
different types of component transfused were not stated,
which limits our interpretation slightly; however, one
could conclude that many of these transfusions were
unnecessary. If transfusion does cause organ injury and
adverse outcome, many of these patients suffered unnec-
essarily as a result. The answers to this however are that,
firstly, where is the evidence of cause and effect, and sec-
ondly, what is or is not a necessary transfusion.
The strong associations between transfusion and adverse
outcome and the variability in transfusion practice are
strong arguments for a randomised trail in cardiac surgery.
This should attempt to determine whether more transfu-
sion is harmful than less transfusion. The TITRe2 (for
'Transfusion Indication Threshold Reduction on transfu-
sion rates') trial, a multicentre randomised controlled trial
of transfusion indication threshold reduction on transfu-
sion rates, morbidity and healthcare resource use follow-
ing cardiac surgery, is a UK National Institute for Health
Research-funded study that will attempt to address this
issue. A total of 2,000 patients in 10 UK cardiac centres
will be randomised to either a restrictive transfusion
threshold of 7.5 g/dL or a liberal threshold of 9 g/dL, with
ischaemic and septic complications as a co-primary end-
point. The choice of thresholds is pragmatic, and reflects
the range of haemoglobin over which the vast majority of
transfusions are administered in clinical practice [10].
Whether these thresholds will reflect accurate transfusion
indicators is another matter, and in all likelihood several
trials will be required to define groups of patients where
transfusion is beneficial. These trials are difficult to per-
form, not least because blood is transfused according to a
medical theology where clinicians often have strong views
as to when transfusions should be administered, despite
the lack of available evidence, and resistance to enrolment
is more common from clinicians, rather than patients. If,
as suggested by Rogers and colleagues, transfusion harms
more often than it helps however, we as clinicians have a
duty to find out.
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